Abstract
Purpose :
To investigate predictive factors for metamorphopsia after reduced-fluence photodynamic therapy (RFPDT) in central serous chorioretinopathy (CSC) patients with good visual acuity at baseline.
Methods :
26 eyes of 26 consecutive patients with resolved CSC after RFPDT and best-corrected visual acuity (BCVA) better than 0.6 (74 letters in ETDRS chart) were retrospectively reviewed. We measured metamorphopsia using M-CHARTS at 6 months after RFPDT. A greater one of the horizontal and vertical M-CHARTS scores was applied for the extent of metamorphopsia. Patients were divided into 2 groups depending on the presence or absence of metamorphopsia defined as M-CHARTS score equal to or greater than 0.5°; M (+) group (n=14, M-CHARTS score≧0.5°), or M (-) group (n=12, M-CHARTS score<0.5°). We investigated the differences in age, sex, time of duration, baseline BCVA, and findings of optical coherence tomography (OCT) between groups.
Results :
Duration of symptom in M (+) group was significantly longer compared with that in M (-) group. (P=0.027). Outer nuclear layer (ONL) thickness before RFPDT was significantly thinner in M (+) group than M (-) group (P=0.020). In the multivariate analysis, thinner ONL thickness before RFPDT (P=0.014) was related to large metamorphopsia in CSC patients with good BCVA at baseline.
Conclusions :
ONL thickness may be useful as predictive factors for metamorphopsia after RFPDT in CSC patients with good BCVA at baseline.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.